Search Results

Bio-Techne Corporation (NASDAQ:TECH), today announced it has completed the acquisition of Namocell, Inc.

Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Namocell, Inc.

Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell ™ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamines, and trans-ISRIB (CEPT) cocktail.

HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like cells differentiated from adipose tissue-derived stromal cells using Namocell’s Single Cell Dispensers and Takara Bio’s SMART-seq® kits to characterize HepaTx’s novel cell therapies for liver disease.

Namocell Inc. announced that it has entered into a collaboration with Takara Bio and HepaTx to use Namocell’s Single Cell Dispensers to perform single cell isolation on HepaTx’s unique hepatocyte-like cells developed from adipose tissue-derived stromal cells, and characterize them by single cell RNA-seq using Takara Bio’s SMART-Seq technology.

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights: • Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive • Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources • Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception • 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027